Unanswered questions in including HDL-cholesterol in the cardiovascular risk estimation. Is time still on our side?

Atherosclerosis

Volumn 226, Issue 1, 2013, Pages 296-298

  Langlois, Michel R ^a,b   Delanghe, Joris R ^a   De Buyzere, Marc ^a   Rietzschel, Ernst ^a   De Bacquer, Dirk ^a  

^a GHENT UNIVERSITY   (Belgium)

^b AZ St Jan ^*  (Belgium)

Author keywords

Analytical variation; Cardiovascular risk; HDL subclasses; HDL cholesterol; SCORE; Standardization

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROGOL; TRIACYLGLYCEROL;

ACCURACY; CARDIOVASCULAR RISK; CLINICAL OBSERVATION; HUMAN; LETTER; LIPID ANALYSIS; PRECIPITATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL; ULTRACENTRIFUGATION;

CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; HEMATOLOGIC TESTS; HUMANS; RISK ASSESSMENT;

EID: 84871382711     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.10.036     Document Type: Letter

References (22)

1. Catapano A.L., Reiner Z., De Backer G., et al. ESC/EAS guidelines for the management of dyslipidaemias. The task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011, 217:3-46.
2. Descamps O.S., Cooney M.T., De Backer G., Graham I. A simple multiplier to calculate the impact of HDL cholesterol on cardiovascular risk estimation using SCORE. Atherosclerosis 2012, 222:564-566.
3. Cooney M.T., Dudina A., De Bacquer D., et al. HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk. Atherosclerosis 2009, 206:611-616.
4. Haase C.L., Tybjærg-Hansen A., Qayyum A.A., Schou J., Nordestgaard B.G., Frikke-Schmidt R. LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals. J Clin Endocrinol Metab 2012, 97:E248-E256.
5. Voight B.F., Peloso G.M., Orho-Melander M., et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. The Lancet 2012, 380:572-580.
6. Langlois M., Blaton V. Historical milestones in the measurement of HDL cholesterol: impact on clinical and laboratory practice. Clin Chim Acta 2006, 369:168-178.
7. Warnick G.R., Nauck M., Rifai N. Evolution of methods for measurement of HDL-cholesterol: from ultracentrifugation to homogeneous assays. Clin Chem 2001, 47:1579-1596.
8. Rietzschel E.R., De Buyzere M.L., Bekaert S., et al. Rationale, design, methods and baseline characteristics of the Asklepios study. Eur J Cardiovasc Prev Rehabil 2007, 14:179-191.
9. De Bacquer D., De Backer G. The prevalence of concomitant hypertension and hypercholesterolaemia in the general population. Int J Cardiol 2006, 110:217-223.
10. Cobbaert C., Zwang L., Ceriotti F., et al. Reference standardization and triglyceride interference of a new homogeneous HDL-cholesterol assay compared with a former chemical precipitation assay. Clin Chem 1998, 44:779-789.
11. Jensen T., Truong Q., Frandsen M., Dinesen B., Stender S. Comparison of a homogeneous assay with a precipitation method for the measurement of HDL cholesterol in diabetic patients. Diabetes Care 2002, 25:1914-1918.
12. Miller W.G., Myers G.L., Sakurabayashi I., et al. Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. Clin Chem 2010, 56:977-986.
13. Vesper H.W., Wilson P.W.F., Rifai N. A message from the laboratory community to the National Cholesterol Education Program Adult Treatment Panel IV. Clin Chem 2012, 58:523-527.
14. Warnick G.R., Wood P.D., for the National Cholesterol Education Program Working Group on Lipoprotein Measurement National Cholesterol Education Program recommendations for measurement of high-density lipoprotein cholesterol: executive summary. Clin Chem 1995, 41:1427-1433.
15. Rosenson R.S., Brewer H.B., Chapman M.J., et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem 2011, 57:392-410.
16. Ansell B.J., Watson K.E., Fogelman A.M., Navab M., Fonarow G.C. High-density lipoprotein function: recent advances. J Am Coll Cardiol 2005, 46:1792-1798.
17. Rajesh Movva R., Rader D.J. Laboratory assessment of HDL heterogeneity and function. Clin Chem 2008, 54:788-800.
18. Kimberly M., Leary E.T., Cole T.G., Waymack P.P., for the Cholesterol Reference Method Laboratory Network Selection, validation, standardization, and performance of a designated comparison method for HDL-cholesterol for use in the cholesterol reference method laboratory network. Clin Chem 1999, 45:1803-1812.
19. Sniderman A.D., Williams K., Contois J.H., et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 2011, 4:337-345.
20. Contois J.H., Warnick G.R., Sniderman A.D. Reliability of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B measurement. J Clin Lipidol 2011, 5:264-272.
21. Walldius G., Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy - a review of the evidence. J Intern Med 2004, 255:188-205.
22. Langlois M.R. Laboratory approaches for predicting and managing the risk of cardiovascular disease: postanalytical opportunities of lipid and lipoprotein testing. Clin Chem Lab Med 2012, 50:1169-1181.